Get started
Author

Masato Saito

Observed name: M. Saitou
Institution: Kyowa Kirin (Japan)
ORCID: 0000-0002-5384-3787
Observed ORCID: 0000-0002-5384-3787
OpenAlex ID: A5007860318
Anti-inflammatory Effects of Bacteroidota Strains Derived From Outstanding Donors of Fecal Microbiota Transplantation for the Treatment of Ulcerative Colitis
2024 · Dai Ishikawa, Xiaochen Zhang, et al. · Inflammatory Bowel Diseases · 32
Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma
2019 · Yui Suzuki, Masato Saito, et al. · Clinical Cancer Research · 29
Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma
2020 · Masato Saito, Toshihiko Ishii, et al. · Blood Advances · 19
Regulatory T‐cells activated in metastatic draining lymph nodes possibly suppress cancer immunity in cancer tissues of head and neck squamous cell cancer
2024 · Susumu Suzuki, Toyonori Tsuzuki, et al. · Pathology International · 4
The novel and potent CD40 agonist KHK2840 augments the antitumor efficacy of anti‐ PD ‐1 antibody and paclitaxel
2024 · Chiaki Kobayashi, Minami Suzuki‐Imaizumi, et al. · Cancer Science · 3
PDF
Abstract 5311: KK2269, an epithelial cell adhesion molecule-targeted CD40 agonist, stimulates anti-tumor immunity resulting in sustained anti-tumor effect against mouse intrahepatic tumor without hepatotoxicity
2024 · Yoshiki Sumitomo, Kyoko Kawasaki, et al. · Cancer Research · 2
Identification of an aberrant type of rearrangement in the T-cell receptor α/δ locus in adult T-cell leukemia
2001 · M. Saitou, N. Sadamori, et al. · Journal of Human Genetics · 2
Docetaxel‐Induced Immune Activation Shows Antitumor Synergy With the Tumor‐Targeted CD40 Agonist KK2269
2026 · Yuta Tezuka, Kyoko Kawasaki, et al. · Cancer Science · 1
A selective IDO1 inhibitor, KHK2455, improves efficacy of PD-L1 blockade by modulating both innate and adaptive immunity in a mouse melanoma model
2025 · Masato Saito, Kana Kunieda, et al. · Cancer Immunology Immunotherapy · 1
PDF
Abstract 5310: KK2269, an epithelial cell adhesion molecule-targeted CD40 agonist, demonstrates antitumor effects in combination with standard therapies for NSCLC
2024 · Yuta Tezuka, Kyoko Kawasaki, et al. · Cancer Research · 1
37 Circulating extracellular vesicle proteomics identifies candidate pharmacodynamic biomarkers for tumor-targeted CD40 agonist KK2269 in a mouse tumor model
2026 · Masato Saito, Tomoyuki Naoi · Journal for ImmunoTherapy of Cancer
PDF
Supplementary Data from Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma
2023 · Yui Suzuki, Masato Saito, et al.
Data from Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma
2023 · Yui Suzuki, Masato Saito, et al.
Data from Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma
2023 · Yui Suzuki, Masato Saito, et al.
Monitoring of Adult T-Cell Leukemia-Lymphoma Cells in Patients Receiving Mogamulizumab, a Humanized Anti-CCR4 Monoclonal Antibody, Using T-Cell Receptor Repertoire Analysis
2016 · Masato Saito, Takashi Ishida, et al. · Blood
Works count: 15
Citation count: 94
H-index: 4
I10-index: 3
Year
Topic
Type